Mutibagger Healthcare Service Company Announces Rs 12,540.68 Million AHLL Stake Acquisition and Rs 5,730 Million Investment in Gurugram Oncology Centre

Apollo Hospitals Enterprise Limited (AHEL), a Large-Cap healthcare provider, announced two major strategic initiatives following its Board of Directors meeting held on September 12, 2025. The company will consolidate its ownership in Apollo Health and Lifestyle Limited (AHLL) and invest in a new oncology centre in Gurugram. These moves strengthen Apollo’s integrated healthcare network and are aligned with its long-term growth strategy.

AHEL approved the purchase of 41,650,368 equity shares in AHLL, representing a 30.58 per cent equity stake, from the International Finance Corporation (IFC) and IFC EAF Apollo Investment Company. The total transaction value is Rs 12,540.68 million at Rs 301.09 per share. Post-acquisition, AHLL will become a 99.42 per cent subsidiary of AHEL, with the balance 0.58 per cent reserved under an ESOP pool. This deal is subject to Competition Commission of India approval and is expected to close by November 2025. AHLL, incorporated in 2000, operates speciality hospitals, diagnostic centres, birthing clinics, sugar clinics, dental and dialysis centres. For FY 2024-25, AHLL reported revenue of Rs 15,535 million, compared to Rs 13,653 million in FY 2023-24 and Rs 12,311 million in FY 2022-23. With full ownership, Apollo plans to scale AHLL across four verticals – diagnostics, birthing and women’s health, ambulatory care centres, and dialysis and dental networks. The acquisition is expected to improve operational integration, capital efficiency, and returns.

In addition, Apollo announced an investment of Rs 5,730 million to establish a 100-bed Comprehensive Oncology Centre in Gurugram. The facility will feature next-generation Proton Therapy technology through the Proteus One System and will be part of Apollo’s upcoming 500-bed hospital in the city. The project will be financed through internal accruals and is expected to be completed by FY 2029. This will be Apollo’s third Proton Therapy installation after Chennai and Hyderabad. The new centre will enable treatment of 350 patients annually, strengthening Apollo’s oncology network. With this expansion, Apollo aims to double the scale of its oncology business to Rs 50,000 million in the next 3–4 years.

Over the past year, the stock has risen 13.42 per cent, outperforming the Nifty’s 1.08 per cent decline. In the last five years, the stock has delivered multibagger returns of 361 per cent. The company boasts a market cap of Rs 1,13,000 crore.

About the Company

Apollo Hospitals, India’s first corporate hospital, has been a pioneer in private healthcare and has evolved into Asia’s leading integrated healthcare provider. With a robust presence across hospitals, pharmacies, diagnostic clinics, and retail health models, the company continues to set new benchmarks in medical excellence.

Disclaimer: The article is for informational purposes only and not investment advice.